Literature DB >> 3569251

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

D Seal, S P Borriello, F Barclay, A Welch, M Piper, M Bonnycastle.   

Abstract

Two patients with relapsing Clostridium difficile diarrhoea following metronidazole and vancomycin therapy were colonised with a non-toxigenic avirulent Clostridium difficile strain given orally in three doses. Both patients appeared to respond without side-effects. Oral bacteriotherapy with a defined nontoxigenic strain of Clostridium difficile would appear to represent an acceptable, alternative and novel way to treat hospitalised patients who relapse with Clostridium difficile diarrhoea after specific antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569251     DOI: 10.1007/bf02097191

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  8 in total

1.  Simplified procedure for tissue culture in routine detection of cytotoxins.

Authors:  A R Welch; S P Borriello; F E Barclay
Journal:  J Clin Pathol       Date:  1985-07       Impact factor: 3.411

2.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

3.  Simplified procedure for the routine isolation of Clostridium difficile from faeces.

Authors:  S P Borriello; P Honour
Journal:  J Clin Pathol       Date:  1981-10       Impact factor: 3.411

4.  Treatment of antibiotic-associated enterocolitis with vancomycin.

Authors:  R Fekety; J Silva; J Armstrong; M Allo; R Browne; J Ebright; R Lusk; G Rifkin; R Toshniwal
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

5.  Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains.

Authors:  S P Borriello; F E Barclay
Journal:  J Med Microbiol       Date:  1985-06       Impact factor: 2.472

6.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces.

Authors:  A Schwan; S Sjölin; U Trottestam; B Aronsson
Journal:  Scand J Infect Dis       Date:  1984

7.  Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis.

Authors:  K H Wilson; J Silva; F R Fekety
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

8.  Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.

Authors:  T A Bowden; A R Mansberger; L E Lykins
Journal:  Am Surg       Date:  1981-04       Impact factor: 0.688

  8 in total
  33 in total

1.  Gender Differences in Non-Toxigenic Clostridium difficile Colonization and Risk of Subsequent C. difficile Infection.

Authors:  Mukil Natarajan; Mary Am Rogers; Jacob Bundy; Dejan Micic; Seth T Walk; Kavitha Santhosh; Krishna Rao; Spencer Winters; Vincent B Young; David M Aronoff
Journal:  Clin Res Infect Dis       Date:  2015-08-03

Review 2.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 3.  Clostridium difficile: an emerging pathogen in children.

Authors:  Natalia Khalaf; Jonathan D Crews; Herbert L DuPont; Hoonmo L Koo
Journal:  Discov Med       Date:  2012-08       Impact factor: 2.970

4.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

5.  The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.

Authors:  Keshan Zhang; Song Zhao; Yuankai Wang; Xuejun Zhu; Hong Shen; Yugen Chen; Xingmin Sun
Journal:  Anaerobe       Date:  2015-10-13       Impact factor: 3.331

6.  Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Authors:  S M Klein; G W Elmer; L V McFarland; C M Surawicz; R H Levy
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

7.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

8.  A molecular characterization of Clostridium difficile isolates from humans, animals and their environments.

Authors:  G O'Neill; J E Adams; R A Bowman; T V Riley
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

Review 9.  Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology.

Authors:  P G Falk; L V Hooper; T Midtvedt; J I Gordon
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

Review 10.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.